#	Pagina
attuale pagina	/open-h2020/projects/211448/index.html

Opendata, web and dolomites

Fertissimo SIGNED

A ground-breaking medical system selecting the most viable embryo for successful IVF pregnancy

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

Fertissimo project word cloud

Explore the words cloud of the Fertissimo project. It provides you a very rough idea of what is the project "Fertissimo" about.

single certify qualified benefit solid retrospective os profile practiced dependable chances accurate culture series viability conduct costly legacy ivi met utilises valencia embryo procedure oxidative accommodate forces outcomes tools mothers transfer conclusive manner finances pregnancies physician riskier media basis innovation infrastructure medical clinics mass qualify engineering low unable stress foundation company rate standard hospitals industrially leader minimise embryos fertissimo soon located facilities equates ultimate forming prospective biomarker efficient global pregnancy aran diagnostics carmel clinical joins incubated quantitative invasive ivf trial unprecedented excellence line multiple reproductive 2009 25 predict risk gold rates validation lay morphology rapid create qualities centres

Project "Fertissimo" data sheet

The following table provides information about the project.

Coordinator	CARMEL DIAGNOSTICS LTD Organization address address: 9 BARLEV HAIM STREET city: QIRYAT TIVON postcode: 3608267 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Israel [IL]
Project website	http://www.fertissimoivf.com
Total cost	2˙751˙973 €
EC max contribution	2˙711˙973 € (99%)
Programme	1. H2020-EU.3.1.3. (Treating and managing disease)
Code Call	H2020-SMEINST-2-2016-2017
Funding Scheme	SME-2
Starting year	2017
Duration (year-month-day)	from 2017-05-01 to 2020-04-30

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	CARMEL DIAGNOSTICS LTD CARMEL DIAGNOSTICS LTD Organization address address: 9 BARLEV HAIM STREET city: QIRYAT TIVON postcode: 3608267 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IL (QIRYAT TIVON)	coordinator	1˙446˙486.00
2	ARAN RESEARCH DEVELOPMENT & PROTOTYPES LTD ARAN RESEARCH DEVELOPMENT & PROTOTYPES LTD Organization address address: 43 HAESHEL ST city: CAESAEA postcode: 38900 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IL (CAESAEA)	participant	1˙265˙487.00

Map

Project objective

Low rates of pregnancy in IVF procedure is due to being unable to identify viable embryos for transfer. As a result, multiple embryo transfer (MET) is practiced to increase the chances of pregnancy. This is a costly procedure with riskier outcomes, which on average only equates to a 1 out of 4 rate of pregnancy success. In order to minimise the cost and risk outcomes with MET, there are increasing trends have been adopted to accommodate single embryo transfer (SET). SET however, requires more efficient embryo selection tools than current legacy morphology methods.

Fertissimo utilises a novel biomarker of oxidative stress (OS) qualities that will enable the physician’s selection of viable embryos in a rapid, non-invasive, and accurate manner. Fertissimo will provide a quantitative assessment of an embryo’s reproductive potential based on the oxidative profile of its incubated culture media. It will increase IVF pregnancy outcomes by an unprecedented 25% and beyond.

The Phase 2 project’s ultimate aim is to lay the foundation for dependable IVF pregnancies of the future. Fertissimo will set the gold standard for IVF procedure in all relevant IVF facilities, located in hospitals, medical centres, centres of IVF excellence, and clinics. Carmel Diagnostics will conduct a series of clinical validation studies, both retrospective and prospective, in order to qualify the novel OS biomarker to effectively predict embryo viability

Carmel Diagnostics (established in 2009) joins forces with Aran R&D, a leading engineering and product development company, forming a solid basis with all necessary knowledge capabilities, infrastructure and finances to support the innovation project. This would allow Carmel, and Aran, to develop, test, certify, and create the production line required for Fertissimo’s mass production.

The industrially produced Fertissimo can then be qualified in a conclusive clinical trial with Global IVF Leader IVI Valencia to the benefit of soon-to-be mothers

Deliverables

List of deliverables.
Original Investor Relations Kit Dossier	Websites, patent fillings, videos etc.	2019-03-20 11:46:21
Project website	Websites, patent fillings, videos etc.	2019-03-20 11:46:21

Take a look to the deliverables list in detail: detailed list of Fertissimo deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "FERTISSIMO" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "FERTISSIMO" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination